PDCD1 and squamous cell carcinoma: Importantly, compared to traditional therapies, the analysed immunotherapies with antibodies blocking the PD-1/PD-L1 pathway show more satisfactory therapeutic effects and lower toxicity, and improves treatment outcomes in patients with advanced squamous cell carcinoma of the head and neck [323,447].